The influence of ezetimibe and simvaststin on platelet aggregation and protein c system in patients with coronary heart disease and hypercholesterolemia

Therapy with ezetimib (10 mg daily for 2 weeks) caused a 24% reduction of plasma LDL cholesterol level (p < 0.05) and maximum ADP and collagen-induced platelet aggregation from 76.2 +/- 1.54 to 65.3 +/- 3.38% and from 71.5 +/- 3.98 to 53.6 +/- 5.24% (p < 0.05) respectively. Combination of ezetimibe and simvaststin did not produce an additional decrease in platelet aggregation.